Adcytherix is a clinical‑stage biopharma that creates next‑generation antibody‑drug conjugates (ADCs) by linking clinically validated antibodies to innovative payloads derived from already approved cancer drugs. Their platform uses advanced conjugation chemistry to improve stability, control payload release, and overcome resistance mechanisms, expanding the therapeutic window for high‑unmet‑need solid tumors. The company’s pipeline targets cancers that are refractory to existing ADCs, offering more precise and tolerable oncology therapies.
Funding
$32.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current antibody‑drug conjugates (ADCs) often face resistance mechanisms, limited therapeutic windows, and suboptimal payload release, restricting their effectiveness against many solid tumors and high‑unmet‑need cancers.
Solution
Adcytherix addresses these limitations by engineering next‑generation ADCs that combine clinically validated antibody targets with innovative payloads derived from already approved cancer drugs. Their platform focuses on sophisticated conjugation chemistry to fine‑tune stability and controlled payload release, aiming to overcome resistance and expand the therapeutic window. By leveraging known drug molecules as payloads, they reduce development risk while delivering higher precision and tolerability. The company advances multiple clinical‑stage candidates designed for cancers that are refractory to existing ADCs, positioning its pipeline to meet critical unmet medical needs in oncology.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing oncology therapeutics, as well as oncologists and clinical research organizations seeking advanced ADC candidates for resistant cancers.
Features
- Utilization of approved oncology drugs as ADC payloads to enhance safety and accelerate development
- Advanced conjugation engineering that balances plasma stability with efficient intracellular payload release
- Targeted antibody selection based on clinically validated antigens for high specificity
- Design strategies specifically aimed at overcoming resistance mechanisms seen with first‑generation ADCs
- Clinical‑stage pipeline focused on high‑unmet‑need solid tumor indications